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Background: Reducing rescue medication use is a guideline-defined goal of asthma treatment, however, little is
known about the validity of rescue medicine use as a marker of symptoms in chronic obstructive pulmonary
disease (COPD). To improve patient outcomes, greater insight is needed into the relationship between rescue
medication use and alternative COPD outcomes.
Methods: A systematic search of electronic databases (Embase®, MEDLINE® and Cochrane CENTRAL) was
conducted from database start to 26 May, 2015. Studies of bronchodilator therapy with a duration of ≥24 weeks
were included if they reported either mean change from baseline (CFB) in rescue medication use in puffs/day or
% rescue-free days (%RFD), and at least one other COPD endpoint. Correlation and meta-regression analyses were
undertaken to test the association between rescue medication use and other COPD outcomes using weighted
means (weights proportional to the sample size of the treatment group) and unweighted means (equal weight for
each treatment group). Each association was assessed at 6 months and study end.
Results: Forty-six studies involving 46,531 patients provided mean data from 145 treatment groups for evaluation.
Changes in both measures of rescue medication use were correlated with changes in trough forced expiratory
volume in one second ([FEV1]; Pearson correlation coefficients |r| ≥ 0.63; p < 0.0001) and with St George’s Respiratory
Questionnaire (SGRQ) score (|r| ≥ 0.70; p < 0.0001) at study end. Change in rescue medication use in puffs/day
during the study correlated with annualized rates of moderate/severe exacerbations at 6 months and study end
(both r = 0.66; p ≤ 0.0028). CFB in puffs/day was not well correlated with Transition Dyspnoea Index (TDI), but %RFD
did correlate with TDI score at 6 months and study end (both r = 0.69; p < 0.0001). The values for CFB in puffs/day
corresponding to the proposed minimal clinically important differences for trough FEV1 and SGRQ score were -1.3
and -0.6 puffs/day, respectively. A -1.0 puffs/day CFB in rescue use corresponded to a change of 0.26 events/
patient-year in moderate/severe exacerbations.
Conclusion: This analysis provides clear evidence of associations at a patient group level between rescue
medication use and other clinically important COPD outcomes.
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Chronic obstructive pulmonary disease (COPD) is a pro-
gressive disease of the respiratory system and is character-
ized by chronic airway inflammation [1, 2]. Spirometry
assessments are important for the characterization and
management of COPD, but the Global initiative for
chronic Obstructive Lung Disease (GOLD) guidelines rec-
ommend that the symptoms experienced by each individ-
ual patient and their exacerbation history should also be
considered [2]. Furthermore, individual studies and meta-
analyses have shown variable levels of correlation between
the spirometric measure of forced expiratory volume in
one second (FEV1) and health status scores [3–6]. For ex-
ample, in the TORCH study, a deterioration in health sta-
tus (assessed by the St George’s Respiratory Questionnaire
[SGRQ]) at 3 years correlated significantly but relatively
poorly with change in FEV1 (r = −0.24; p < 0.0001) [4]. A
more recent meta-analysis that assessed spirometric
measurements and patient-reported outcomes found a
much stronger correlation between trough FEV1 and
SGRQ (r = -0.68; p < 0.0001) [6].
Rescue medication use is commonly measured in clin-
ical trials of patients with asthma and COPD. However,
whilst asthma guidelines focus on minimizing the need
for rescue therapy [7], far less emphasis is placed on
rescue therapy in COPD. To the best of our knowledge,
no previous systematic reviews have assessed the associ-
ation between increased rescue medication use and
other clinical trial outcomes such as changes in troughData sources
Clinical databases: 
• Embase®
• MEDLINE®
• MEDLINE® In-Process
• Cochrane Library
• NIHR-HTA Database
Conferences:
• American Thoracic Society
• European Respiratory Society
• British Thoracic Society
• The American College of Chest Physicians
Other sources: 
• ClinicalTrials.gov of the US NIH
• International Clinical Trials Registry Platform 
 Search Portal (WHO meta-registry)
• Current Controlled Trials
• EU Clinical Trials Register
 (www.clinicaltrialsregister.eu)
• International Prospective Register of
Systematic Reviews
• Guidelines International Network
• HTA agencies
• Targeted hand search of FDA and 
EMA websites
Populat
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Fig. 1 Data sources and selection criteria for the review. Abbreviations: COP
Agency; Embase Excerpta Medica Database; FDA Food and Drug Administra
LABA long-acting β2-agonist; LAMA long-acting muscarinic antagonist; MED
National Institute for Health Research; WHO World Health OrganizationFEV1, incidence of moderate-to-severe COPD exacerba-
tions or patient-reported outcomes such as SGRQ or the
Transition Dyspnoea Index (TDI) [5, 6]. Recently,
increased levels of rescue medication use and temporal
changes in its use have been linked with increased
exacerbation risk in patients with moderate-to-very-
severe COPD [3]. Whether this finding can be confirmed
across multiple randomized controlled trials (RCTs)
remains to be established. The primary objective of the
current analysis was to assess the relationship between
rescue medication use and other COPD outcomes
measured in clinical trials.
Methods
Sources
Systematic searches of the literature were performed
using a predefined search strategy to identify studies in
COPD. A range of data sources were searched from
database start to 26 May, 2015, including clinical trial
databases, clinical trial registries and conferences, and
the results were supplemented with information
retrieved from other relevant websites (Fig. 1). This
review included a new analysis of data from a previous
systematic literature review [6] and data found in a
subsequent systematic literature search.
Search strategy and selection criteria
Specific search strings were devised for the databases to
be searched and are shown in Additional file 1: Table S1.Interventions
LABA:
• Salmeterol
• Formoterol
• Indacaterol
• Vilanterol
• Olodaterol
LAMA:
• Aclidinium
• Tiotropium
• Glycopyrronium
• Umeclidinium
LABA+LAMA:
• Umeclidinium/vilanterol
• Aclidinium/formoterol
• Tiotropium/olodaterol
• Indacaterol/glycopyrronium
ion characteristics
ears
nt with COPD
D chronic obstructive pulmonary disease; EMA European Medicines
tion; HTA Health Technology Assessment; ICS inhaled corticosteroid;
LINE Medical Literature Analysis and Retrieval System Online; NIHR
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ventions for inclusion (long-acting β2-agonists [LABAs]:
formoterol, indacaterol, olodaterol, salmeterol, vilanterol;
long-acting muscarinic antagonists [LAMAs]: aclidinium,
glycopyrronium, tiotropium, umeclidinium; LABA+LAMA:
aclidinium/formoterol, indacaterol/glycopyrronium, tiotro-
pium/olodaterol, umeclidinium/vilanterol).
The inclusion criteria employed in this analysis were
consistent with those employed in the previous analysis
[6]. Only studies with the full texts published in English
language were included. Eligible studies were RCTs of
≥24 weeks’ duration that enrolled patients of any gender
or race, who were aged ≥18 years and had COPD (as de-
fined by GOLD criteria [2]). Studies that enrolled a
mixed population of patients with asthma and COPD
were only included if subgroup data were available for
the COPD population. Case series, case studies and case
reports were excluded due to their smaller size, non-
comparative nature and higher risk of bias versus RCTs.
Only studies that reported rescue medication use and at
least one other outcome used in COPD trials were
included. The rescue medication data included were
expressed as change from baseline in either mean puffs/
day or percentage of rescue-free days. Other outcomes
used in COPD included were: trough FEV1, TDI focal
score, SGRQ total score and annualized exacerbation
rate. Eligible studies included at least one treatment arm
with an inhaled LABA, LAMA or LABA + LAMA com-
bination. Studies that included a treatment of interest in
combination with treatments not of interest, such as an
inhaled corticosteroid (ICS)/LABA combination, without
an additional LAMA, LABA or LAMA+ LABA arm,
were excluded. There were no other restrictions on the
inclusion of studies.
Bibliographic details, abstracts and titles of all citations
identified by the literature search were imported into a
database, which was used for first pass and second pass
of the citations, as well as data extraction. Two inde-
pendent reviewers first screened the abstracts of all cita-
tions (first pass); if they met the study selection criteria,
the full-text citations were screened (second pass). Any
discrepancies between the reviewers’ decisions at either
stage were resolved by a third independent reviewer.
Any duplicates of citations were also excluded at first
pass stage; any similar publications containing the same
data were linked at the publication stage. Risk of bias in
studies was assessed at the study level using a critical
appraisal checklist [8].
Data extraction
Data extraction was performed using a standardized pre-
piloted data extraction form. Data were extracted in parallel
by two independent reviewers from the text and tables of
documents for the following time points: baseline, 6 monthsand study end. In cases where data were only available in
figures, data were extracted using Engauge Digitiser soft-
ware. For each study treatment group, endpoint of interest,
and selected time points, mean change from baseline, mean
baseline and mean follow-up values were extracted. In cases
where mean changes from baseline values were not avail-
able, these were calculated at the analysis stage from the
mean value at follow-up minus the mean value at baseline.
A review of the distribution of all values was conducted by
the researchers and analytical lead to identify outliers,
which were cross-checked against the source document
and confirmed or modified if required.
Statistical analysis
Study and patient characteristics, as well as outcome
results, were described at treatment group level and
summarized at study level across all studies. These data
were summarized within and across studies using equal
weights for each study treatment group (unweighted
approach) and by using weights proportional to the
study treatment group size. Weights were calculated as
the treatment group sample size divided by the total
number of patients across all treatment groups. The
primary analysis and data interpretation used the
weighted data.
Pearson correlation and linear regression analyses
were used to assess the relationship between rescue
medication use and COPD outcomes and were per-
formed separately for all trials. Analyses were conducted
only for the combination of outcomes for which data
from at least 15 study treatment groups were available.
The sample size allowed the detection of a correlation
coefficient of 0.7 with 90% power and an associated type
I error of 0.05.
Pearson correlation coefficients (weighted analysis)
were determined with their 95% confidence intervals
(CI). Correlation coefficients were weighted by study
treatment group sample size to compensate for variabil-
ity in sample sizes across studies. Interpretation of the
amplitude of the absolute values of correlation coefficients
were based on Cohen’s conventions (0.1–0.3, small/weak;
0.3–0.5, medium/moderate; >0.5, large) [8, 9]. The associ-
ations between rescue medication use and COPD out-
comes were represented visually using bubble plots
(weighted analysis). Each bubble represents a study treat-
ment group and the size of a bubble is proportional to the
study treatment group sample size divided by the total
number of patients across all studies.
Linear regression analysis was conducted to identify
the strength and direction of association between rescue
medication use and COPD outcomes and to estimate
rescue medication use values corresponding to proposed
minimal clinically important difference (MCID) values
for COPD outcomes. Regression coefficients were
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of determination (R2) was calculated.
All data processing and analyses were performed with
SAS software v11.2 (SAS Institute, Cary, NC, USA).
Results
Overview and characteristics of included studies
We identified 144 relevant records, of which 46 unique
studies (30 from a previous review [6] and 16 newly
identified studies) fulfilled the inclusion criteria (Fig. 2).
These 46 studies involved 46,531 patients in 145 differ-
ent treatment groups which provided mean data for
evaluation.
Study characteristics
The median study duration was 44 weeks. The majority
(87%) of studies did not allow background LABA use,
although over half (59%) allowed background ICS
treatment. Most had a minimum threshold inclusion
criterion of a smoking history of 10 pack-years (80%).
The most frequent upper thresholds for the FEV1
inclusion criterion were ≤80% (35%) and ≤70% (33%)
(Additional file 1: Table S2). The distribution of study
treatment groups and patients across treatment categor-
ies is provided in Table 1, with most patients receiving
LABA (34.5%), LABA + ICS (20.0%) or LAMA (18.5%).
Population baseline characteristics
A summary of patient characteristics across all 145 treat-
ment groups from the 46 studies are presented inExcluded at first pass (n = 274)
• Study design (n = 46)
• Review (n = 27)
• Study duration (n = 90)
• Pooled analysis (n = 37)
• Intervention (n = 28)
• Meta analysis and systematic
review (n = 30)
• Healthy subjects only (n = 8)
• Disease (n = 8) 
Previous review studies
(n = 30 studies)
Conference searching
(n = 40)
Records included after seco
(n = 10
Records included after r
(n = 48
Records identified through
(n = 52
Embase® (n
Cochrane (n
MEDLINE® In-Pro
Records included after firs
(n = 21
Total records 
(n = 14
After lin
(n = 62 st
16 studi
(n = 62 publi
46 studi
Fig. 2 Results of the literature search and evaluation of identified studies acco
MEDLINE Medical Literature Analysis and Retrieval System OnlineTable 2. The mean (standard deviation) age of patients
was 63.5 (17.4) years and there were more males (68%)
than females. The mean percentage predicted FEV1 was
45.6% (range: 32.8–60.1%). The baseline characteristic
showing the most variability across treatment groups
was disease severity as assessed using GOLD grades [2].
The percentage of patients with moderate COPD
(GOLD grade 2) ranged from 0 to 99.7% and the per-
centage of patients with severe or very severe COPD
(GOLD grades 3 or 4) ranged from 0 to 100% (Table 2).
Correlation analyses between rescue medication use and
COPD outcomes
The Pearson correlation coefficients between mean
change from baseline in rescue medication use and
mean change from baseline in COPD outcomes at
6 months and study end are presented in Table 3.
The mean change from baseline in number of puffs/
day was negatively correlated with mean change from
baseline in trough FEV1 and TDI at both the 6-month
time point (trough FEV1: R
2 = 0.43; TDI: R2 = 0.19) and
study end (trough FEV1: R
2 = 0.55; TDI: R2 = 0.19;
Table 3; Fig. 3a and b). To ensure that the presence of
two treatment groups considerably larger than the
others (from the INVIGORATE study [10]) did not skew
the data, the regression data for association between
mean change from baseline in number of puffs/day and
mean change from baseline in TDI at study end were
reanalyzed without these two treatment groups; no sig-
nificant change in the R2 value was observed. A positivend stage of screening
4)
emoving duplicates
7)
 database searching
9)
 = 312)
 = 148)
cess (n = 69)
t stage of screening
3)
included
4)
king
udies)
es
cations)
es 
No rescue medication
use/qualitative data/rescue
medication use treatment
difference only
(n = 46 studies)
Excluded at second pass (n = 109)
• Study design (n = 12)
• Review (n = 3)
• Study duration (n = 72)
• Pooled analysis (n = 12)
• Meta analysis and 
systematic review (n = 1)
• Intervention (n = 9)
rding to PRISMA. Abbreviations: Embase Excerpta Medica Database;
Table 1 Distribution of study treatment groups and patients
across treatment categories
Treatment
categories
Treatment groups Patients
N % N %
ICS 3 2.07 626 1.35
LABA 51 35.17 16,059 34.51
LABA + ICS 27 18.62 9282 19.95
LABA + LAMA 17 11.72 5842 12.56
LAMA 20 13.79 8618 18.52
Other 3 2.07 299 0.64
Placebo 24 16.55 5805 12.48
Total 145 100 46,531 100
Abbreviations: ICS inhaled corticosteroid, LABA long-acting β2-agonist, LAMA
long-acting muscarinic antagonist
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baseline in puffs of rescue medication per day and both
mean change from baseline in SGRQ score and mean
annualized rate of moderate or severe exacerbations, at
both 6 months (SGRQ score: R2 = 0.31; exacerbation
rate: R2 = 0.44) and study end (SGRQ score: R2 = 0.61;
exacerbation rate: R2 = 0.45; Table 3; Fig. 3c and d).
The overall picture was very similar when rescue medi-
cation use was expressed as change in percentage of res-
cue medication-free days: positive correlations were
observed with changes in trough FEV1 and TDI score at
6 months (trough FEV1: R
2 = 0.18; TDI: R2 = 0.48) and
study end (trough FEV1: R
2 = 0.36; TDI: R2 = 0.48; Table 3;
Additional file 2: Figures S1A and b). A negative correl-
ation was observed with change in SGRQ score at study
end (R2 = 0.49, Table 3; Additional file 2: Figure S1C); theTable 2 Key baseline characteristics summarized across all study tre
Characteristics Patients evaluated
n (missing)
Nb 145 (0)
Age, years 138 (7)
Male, % 143 (2)
Mean duration of COPD, years 46 (99)
Current smokers, % 118 (27)
Mean of pack-years of cigarettes 71 (74)
Mean baseline trough FEV1 (L) 84 (61)
Mean % predicted FEV1 97 (48)
% GOLD grade 2 78 (67)
% GOLD grades 3 and 4 76 (69)
Mean baseline SGRQ score 70 (75)
Mean BDI score 38 (107)
Abbreviations: BDI Baseline dyspnoea index, COPD chronic obstructive pulmonary d
chronic Obstructive Lung Disease, SGRQ, St George’s Respiratory Questionnaire, SD
aThe statistics calculated take into account the treatment group sample size by app
treatment group is proportional to its sample size
bThe total number of patients randomized in all studies was 46,531correlation at 6 months was not significant (R2 = 0.18).
The correlation with mean annualized rate of moderate or
severe exacerbations was moderate but non-significant
(R2 = 0.15) at study end, while there were insufficient data
to assess the correlation at the 6-month time point
(Table 3; Additional file 2: Figure S1D).
The Pearson correlation coefficients between rescue
medication use and COPD outcomes at baseline are
shown in Additional file 1: Table S3. Correlations
between mean trough FEV1 and both rescue medication
use outcomes were significant and large. The correlation
between mean number of puffs/day and mean SGRQ
score at baseline was significant and moderate. In con-
trast, the correlations between percentage of rescue
medication-free days and mean SGRQ score, and
between number of puffs/day and mean baseline
dyspnoea index (BDI) were not significant, and there
were insufficient data to determine the correlation
between percentage of rescue medication-free days and
BDI (Additional file 1: Table S3).
Estimation of rescue medication values corresponding to
MCID for COPD outcomes
The regression slope between mean change from
baseline in number of puffs/day and mean change from
baseline in trough FEV1 at study end showed that a
change of 100 mL in trough FEV1 (the proposed MCID
value for the FEV1 [11]) was associated with a mean
reduction of 1.3 puffs/day (Fig. 3a). Similarly, with the
SGRQ, the established MCID of −4 points [12] was asso-
ciated with a mean reduction of 0.6 puffs/day (Fig. 3c).
The corresponding analysis was not possible with theatment groups (weighteda)
Population estimate
Mean (SD) Median Min–Max
464 (6632) 403 6–1721
63.5 (17.4) 63.6 58.8–68.1
68.3 (153) 68 43–100
8.0 (37.9) 7.1 5.8–11.3
43.2 (127) 42.9 0–65.0
45.2 (98.6) 44.0 34.8–58.5
1.21 (3.65) 1.22 0.89–1.74
45.6 (129) 45.2 32.8–60.1
29 (540) 19 0–99.7
60 (640) 54 0–100
49.4 (79.4) 48.2 38.4–58.6
6.3 (8.4) 6.4 5.1–7.0
isease, FEV1 forced expiratory volume in one second, GOLD Global initiative for
standard deviation
lying weights to each of the characteristics described; the weight for each
Table 3 Pearson correlation coefficients between rescue medication use and other COPD outcomes
Outcome Mean change from baseline in number of puffs/day Mean change from baseline in % of rescue-free days
N Pearson correlation coefficient
[95% CI], p-value
N Pearson correlation coefficient
[95% CI], p-value
Mean change from baseline in trough FEV1
6 months 64 −0.66 [−0.78, −0.49], <0.0001 33 0.43 [0.10, 0.67], 0.0118
Study end 94 −0.74 [−0.82, −0.64], <0.0001 46 0.63 [0.41, 0.77], <0.0001
Mean change from baseline in SGRQ score
6 months 50 0.60 [0.33, 0.72], <0.0001 18 −0.42 [−0.74, 0.05], 0.077
Study end 75 0.78 [0.67, 0.86], <0.0001 31 −0.70 [−0.84, −0.46], <0.0001
Mean TDI
6 months 57 −0.43 [−0.62, −0.19], 0.0007 24 0.69 [0.40, 0.86], <0.0001
Study end 54 −0.43 [−0.63, −0.19], 0.0009 24 0.69 [0.40, 0.86], <0.0001
Mean annualized rate of moderate or severe exacerbations
6 months 17 0.66 [0.27, 0.87], 0.0028 11 Insufficient data
Study end 38 0.66 [0.44, 0.81], <0.0001 24 −0.39 [−0.68, 0.02], 0.0619
These analyses were weighted by study treatment group sample size, and included all trial arms
Abbreviations: CI confidence interval, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in one second, SGRQ St George’s Respiratory
Questionnaire, TDI Transition Dyspnoea Index
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outside the limits of the regression slope (Fig. 3b). The
same pattern was also observed at the 6-month time
point (data not shown).
The equation for the regression slope between mean
change from baseline in number of puffs/day and annual-
ized rate of moderate or severe exacerbations (annualized
exacerbation rate = 1.054 + 0.26 × [rescue medication use
in puffs/day]) suggests that a reduction in rescue medica-
tion use of -1.0 puffs/day corresponds to a decrease in
annualized exacerbation rate of 0.26 events/patient-year.
Discussion
This analysis showed that rescue medication use,
expressed either as change in number of puffs/day or
change in the number of rescue medication-free days, is
associated with other clinically important outcomes in
COPD trials including functional assessments (trough
FEV1), patient-centered outcomes assessing health status
(SGRQ score), dyspnoea (TDI) and annualized rate of
exacerbations. This suggests that rescue medication use
would be a valid measure to include in health technol-
ogy assessments.
The primary analysis showed that an increase in trough
FEV1 from baseline was associated with a decrease in the
number of rescue medication puffs/day. The correlation
between mean change from baseline in puffs/day and
change in trough FEV1 at study end (R
2 = 0.55) was similar
to that reported in an analysis of pooled data from three
studies in which the correlation (R2) at cohort level data
was 0.77 [9]. The association between reduction in puffs/
day and change in mean SGRQ score was slightly stronger
than that seen for FEV1 with a positive correlation atstudy end. The reduction in puffs/day was associated with
an improvement in breathlessness as measured by the
mean change in TDI focal score at 6 months and study
end. However, a stronger association between change in
the percentage of rescue-free days and TDI focal score
was observed at 6 months and study end. This implies that
an increase in rescue medication-free days may be the
stronger indicator of a reduction in breathlessness. Reduc-
tion in puffs/day was associated with a reduction in the
annualized rate of moderate or severe exacerbations at
6 months and study end. Most correlations were the same
or slightly stronger from 6 months to study end. This find-
ing could suggest that any data collected in a 6-month
study is likely to capture the full efficacy benefit of treat-
ment using most common outcome measures.
Recently, it has been reported that levels of daily
short-acting β2-agonist use and temporal changes in
their use in patients with COPD are likely to be an im-
portant risk factor for moderate/severe exacerbations in
higher-risk patients [3]. In support of this, our data also
highlighted a good correlation between increases or
decreases in rescue medication use and annualized
moderate or severe exacerbation rate. It was also
observed that a change from baseline in rescue medica-
tion use of 1.0 puffs/day corresponded to a difference in
annualized moderate or severe exacerbation rate of 0.26
events/patient-year. Although a clinically relevant
change in annualized rate of moderate or severe exacer-
bations has yet to be established, recent large compara-
tor exacerbation studies have reported treatment
differences between 0.11 and 0.30 events/patient-year in
populations with exacerbation rates of at least one
event/patient-year at baseline [14–16].
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Fig. 3 Weighted linear regression bubble plots for associations (study end) between rescue puffs/day and a CFB trough FEV1; b TDI score; c CFB SGRQ
total score; d mean annualized rate of exacerbations. Abbreviations: CFB change from baseline; FEV1 forced expiratory volume in one second; ICS inhaled
corticosteroid; LABA long-acting β2-agonist; LAMA long-acting muscarinic antagonist; PBO placebo; SGRQ St George’s Respiratory Questionnaire; TDI
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tween rescue medication use and other outcomes, we
performed a mapping exercise to establish the change in
rescue medication use that was associated with estab-
lished MCIDs in COPD outcome measures. This was
not possible with the TDI because the mean improve-
ment in score exceeded the MCID even in patients
receiving placebo, which may have been a clinical trial
effect. It was possible to obtain an estimate of the reduc-
tion in puffs/day associated with the MCID in SGRQ
and trough FEV1, but there was a two-fold difference be-
tween the estimates (−0.6 and −1.3 puffs/day, respect-
ively). Variations in estimates such as these are typically
seen with mapping exercises when used to estimate theMCID for a new outcome using different comparators;
to address this, ‘triangulation’ is commonly performed
(using multiple methods and calculating an average). In
this context, it was not possible to obtain an estimate
using the TDI, so a possible MCID value for rescue
puffs/day remains uncertain.
For all outcomes except mean TDI, correlations
with mean changes in number of puffs per day were
stronger than correlations with mean changes in the
percentage of rescue-free days; indeed, correlations of
changes in SGRQ score at 6 months and mean annu-
alized rate of moderate or severe exacerbations at
12 months with changes in the percentage of rescue-
free days were not statistically significant. The reason
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fact that, as independent variables, mean change in
lung function, SGRQ total score and overall moder-
ate/severe exacerbation rate have a capacity for small
incremental changes in proportion to the mean
change in rescue medication puffs/day as a dependent
variable. However, for rescue-free days as a dependent
variable, movement in a population is more restricted,
with many patients grouped at extreme values with
100 or 0% of days rescue-free. As this measure does
not reflect the extent of use on days when rescue
medication is taken, it might be suggested that it pro-
vides a less accurate reflection of disease severity than
the mean number of puffs/day. It is also possible that
patients may use rescue medication prophylactically
(for example, before exercise with the aim of prevent-
ing exercise-induced dyspnea); this may skew data on
the percentage of rescue-free days to a greater extent
than the mean number of puffs/day. The reduced
ability of the percentage of rescue-free days to show
incremental improvement or deterioration from base-
line may more closely align with changes in TDI,
with all data points showing relatively restricted mean
improvement by 1 to 3 units in virtually all study
arms and no mean data points showing deterioration.
This analysis used a large data set obtained in 145
treatment groups containing 46,531 patients from 46
studies, which is a strength. However, a key limitation is
that the data were analyzed using meta-techniques, ra-
ther than pooled individual patient data. Future research
examining patient level data, such as a pooled analysis,
is required to gain a better understanding of how levels
of rescue medication use and changes from baseline in
its use reflect patient burden of disease, using conven-
tional patient-reported outcomes and exacerbation inci-
dence to better estimate a likely MCID for rescue
medication use. More research is also needed into
whether there are identifiable patient demographics or
disease-related factors that can account for differences
between individuals in rescue medication use.
As with all systematic reviews, a limitation is the avail-
ability of data reported from the primary trials. This is well
illustrated by the difference of almost two-fold in the
reporting of FEV1 data compared with exacerbations. An-
other limitation of the method used to estimate an MCID
for rescue medication use came from the performance of
the TDI, for which large improvements were observed even
in patients who received placebo, which presumably reflects
the operation of a large clinical trial effect on this outcome.
One notable omission from this analysis is any correlation
with specific COPD symptoms as measured by an instru-
ment such as the Exacerbations of Chronic Pulmonary
Disease Tool (EXACT)-Respiratory Symptom (E-RS) meas-
ure [17], since this is a newly developed instrument.Conclusions
This analysis shows that a reduction in rescue medica-
tion use is associated with improvement in trough FEV1,
breathlessness and health status, and with the rate of ex-
acerbations during the study period. These associations
were moderate to strong at a study group level, showing
that this outcome may be a surrogate marker of symp-
tomatic benefit in COPD trials. However, confirmation
of this conclusion requires individual patient data
analysis.
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